22:47 , Aug 5, 2019 |  BC Extra  |  Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients  Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by...
18:35 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
14:46 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product...
16:57 , Apr 2, 2018 |  BC Extra  |  Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis...
17:29 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all four doses of RPL554 (VMX554, VRP554) as...
16:40 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced...
00:32 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily 1.5 and 6 mg doses of RPL554 (VMX554, VRP554) plus Spiriva...
03:15 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Verona begins PK trial for RPL554 in healthy volunteers

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) began a 2-way crossover, U.S. trial to evaluate the bioavailability, pharmacokinetics and safety of nebulized RPL554 in 12 healthy volunteers. Data from the trial are expected in 4Q17. The nebulized...
19:01 , Apr 27, 2017 |  BC Extra  |  Financial News

Verona raises $80M, lists on NASDAQ

Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) traded flat on NASDAQ Thursday, ending the day at $13.50, after it raised $80 million in a NASDAQ listing and concurrent private placement, both underwritten by Jefferies,...
04:23 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

RPL554: Ph IIa started

Verona began a double-blind, placebo-controlled, 3-way crossover, U.K. Phase IIa trial to evaluate single doses of 1.5 and 6 mg inhaled RPL554 in about 10 patients. In 2005, Verona licensed the product from Vernalis, which...